FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology and concerns an isolated polypeptide, a pharmaceutical composition containing such polypeptide, as well as a method of treating cancer. The presented polypeptide contains an amino acid sequence corresponding to SEQ. ID. NO: 2 or SEQ ID NO: 4. There are also characterised fragments or versions of the presented polypeptide.
EFFECT: group of inventions may be used to stimulate the immune system in treating malignant diseases and for diagnosing loss of immunologic activity.
7 cl, 7 dwg, 1 tbl, 6 ex
| Title |
Year |
Author |
Number |
| POLYPEPTIDES AND POLYNUCLEOTIDES AND THEIR USE FOR TREATMENT OF IMMUNE DISORDERS AND CANCER |
2012 |
- Toporik Amir
- Novik Amit
- Shemesh Ronen
|
RU2623161C2 |
| POLYPEPTIDES FOR TREATING STRESS SYNDROMES, IMMUNE RESPONSE AND STROKE |
2019 |
|
RU2824567C2 |
| POLYPEPTIDES |
2011 |
- Gaudernakk Gustav
- Rasmussen Anne-Marija
- Suso Else Marit Inderberg
|
RU2581800C2 |
| TREATMENT OF INFLAMMATION, AUTOIMMUNE, AND NEURODEGENERATIVE DISORDERS WITH IMMUNOSUPPRESSIVE TAT DERIVATIVE POLYPEPTIDES |
2013 |
- Goldberg Dzhoshua
- Bir Kolin
- Khotts-Bikhofsits Kristof
- Khenskom Sofi
|
RU2653754C2 |
| THYMUS-SPECIFIC PROTEIN |
2005 |
- Devari, Joram
- Sandler, Uziel'
|
RU2535971C2 |
| HUMAN VISTA ANTIBODIES AND THEIR APPLICATION |
2017 |
- Snajder, Linda
- Pichenik, Dov
- Pauvers, Gordon
- Rotstejn, Dzhej
- Molloj, Majkl
|
RU2746994C2 |
| THYMUS-SPECIFIC PROTEIN |
2005 |
- Devari Joram
- Sandler Uziel'
|
RU2398776C2 |
| PHARMACEUTICAL COMPOSITION POSSESSING ANTITUMOUR EFFECT, AND METHOD FOR REDUCING PD-L1 INHIBITING EFFECT ON HUMAN T-CELLS |
2016 |
|
RU2688692C2 |
| NOVEL ANTIBODIES |
2008 |
- Ljan Vehj-Chin
- Plauman Gregori D.
- U Jan'
- E Vehjlan'
|
RU2490277C2 |
| METHOD FOR TREATING AUTOIMMUNE DISEASE USING BIOCOMPATIBLE BIOABSORBABLE NANOSPHERE |
2011 |
|
RU2635537C2 |
